リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Identification of cisplatin-resistant factor by integration of transcriptomic and proteomic data using head and neck carcinoma cell lines」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Identification of cisplatin-resistant factor by integration of transcriptomic and proteomic data using head and neck carcinoma cell lines

Inukai, Daisuke Nishimura, Kunihiro Okamoto, Hiroki Sano, Rui Ueda, Hiromi Ota, Akinobu Karnan, Sivasundaram Hosokawa, Yoshitaka Yoshikawa, Kazuhiro Suzuki, Susumu Ueda, Ryuzo Murotani, Kenta Bradford, Carol R. Ogawa, Tetsuya 名古屋大学

2020.08

概要

Cisplatin is an important drug for the treatment of head and neck squamous cell carcinoma (HNSCC). Determining chemoresistant factors prior to treatment will lead to great benefits for clinicians and patients. Here, we evaluated chemoresistant factors by integrating proteomic and transcriptomic data using HNSCC cell lines to identify a more precise chemoresistant factor in HNSCC. We used four HNSCC cell lines: cisplatin-sensitive, acquired cisplatin resistance, naturally cisplatin-resistant, and acquired 5-FU resistance. Proteomic analysis was performed using iTRAQ, tandem mass spectrometry, and liquid chromatography-electrospray ionization-tandem mass spectrometry. Transcriptomic analysis was performed using microarrays. By integrating these independent data, common factors were addressed and functional analysis was performed using small interfering RNAs (siRNAs) to change the chemosensitivity. Using iTRAQ analysis, 7 proteins were identified as specific for cisplatin chemoresistance factors. Transcriptomic analysis revealed hundreds of potential candidate factors. By combining and integrating these data, S100A2 was identified as a potential cisplatin-specific chemoresistance factor. Functional analysis with siRNA revealed that the expression of S100A2 was reduced and cisplatin sensitivity recovered in the acquired and naturally cisplatin-resistant cell lines, but not in the cisplatin-sensitive cell lines. S100A2 was identified as a cisplatin-specific chemoresistance factor by integrating the transcriptomic and proteomic results obtained using HNSCC cell lines. This is a novel technique that allows for a precise identification, also known as a comprehensive analysis. Our findings indicate that these proteins could be used as biomarkers of HNSCC treatments, providing physicians with new treatment strategies for patients with HNSCC, showing chemoresistance.

この論文で使われている画像

参考文献

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer

531

Identification of CDDP-resistant factor

in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–2917.

2. Nishimura K, Tsuchiya Y, Okamoto H, et al. Identification of chemoresistant factors by protein expression

analysis with iTRAQ for head and neck carcinoma. Br J Cancer. 2014;111:799–806.

3. Brenner JC, Graham MP, Kumar B, et al. Genotyping of 73 UM-SCC head and neck squamous cell

carcinoma cell lines. Head Neck. 2010;32:417–426.

4. Adachi M, Ijichi K, Hasegawa Y, et al. Hypersensitivity to cisplatin after hRev3 mRNA knockdown in

head and neck squamous cell carcinoma cells. Mol Med Rep. 2008;1(5):695–698.

5. Ijichi K, Adachi M, Hasegawa Y, et al. Pretreatment with 5-FU enhances cisplatin cytotoxicity in head and

neck squamous cell carcinoma cells. Cancer Chemother Pharmacol. 2008;62:745–752.

6. Mizuno S, Hanamura I, Ota A, et al. Overexpression of salivary-type amylase reduces the sensitivity to

bortezomib in multiple myeloma cells. Int J Hematol. 2015;102:569–578.

7. Murata S, Adachi M, Kioi M, et al. Etodolac improves 5-FU sensitivity of head and neck cancer cells

through inhibition of thymidylate synthase. Anticancer Res. 2011;31:2893–2898.

8. Borsellino N, Belldegrun A, Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res.

1995;55:4633–4639.

9. Bradford CR, Zhu S, Ogawa H, et al. P53 mutation correlates with cisplatin sensitivity in head and neck

squamous cell carcinoma lines. Head Neck. 2003;25:654–661.

10. Xu ZY, Loignon M, Han FY, Panasci L, Aloyz R. Xrcc3 induces cisplatin resistance by stimulation of

Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis. J Pharmacol

Exp Ther. 2005;314:495–505.

11. Yamamoto N, Yokoyama S, Ieda J, et al. CEACAM1 and hollow spheroid formation modulate the chemosensitivity of colorectal cancer to 5-fluorouracil. Cancer Chemother Pharmacol. 2015;75:421–430.

12. Bresnick AR, Weber DJ, Zimmer DB. S100 proteins in cancer. Nat Rev Cancer. 2015;15:96–109.

13. Lee J, Wysocki PT, Topaloglu O, et al. Epigenetic silencing of S100A2 in bladder and head and neck

cancers. Oncoscience. 2015;2(4):410–418.

14. Almadori G, Bussu F, Galli J, et al. Diminished expression of S100A2, a putative tumour suppressor, is

an independent predictive factor of neck node relapse in laryngeal squamous cell carcinoma. J Otolaryngol

Head Neck Surg. 2009;38:16–22.

15. Zha C, Jiang XH, Peng SF. iTRAQ-based quantitative proteomic analysis on S100 calcium binding protein

A2 in metastasis of laryngeal cancer. PLoS ONE. 2015;10:e0122322.

16. Wolf S, Haase-Kohn C, Pietzsch J. S100A2 in cancerogenesis: a friend or a foe? Amino Acids.

2011;41:849–861.

17. Kumar M, Srivastava G, Kaur J, et al. Prognostic significance of cytoplasmic S100A2 overexpression in

oral cancer patients. J Transl Med. 2015;13:8.

...

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文

一発検索!

この論文の関連論文を見る